{"id":"placebo-for-ubrogepant","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (ubrogepant) by comparison. Any observed effects in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect itself. This allows researchers to isolate the true therapeutic benefit of ubrogepant.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:27.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment)"}]},"trialDetails":[{"nctId":"NCT05125302","phase":"PHASE3","title":"Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"Migraine","enrollment":1059},{"nctId":"NCT06417775","phase":"PHASE3","title":"Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-09-10","conditions":"Migraine","enrollment":496},{"nctId":"NCT06578585","phase":"PHASE1","title":"A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2024-09-13","conditions":"Migraine","enrollment":43},{"nctId":"NCT04492020","phase":"PHASE3","title":"Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-08-21","conditions":"Migraine","enrollment":518},{"nctId":"NCT02873221","phase":"PHASE3","title":"An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-09-13","conditions":"Migraine, With or Without Aura","enrollment":1254},{"nctId":"NCT02867709","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-08-26","conditions":"Migraine, With or Without Aura","enrollment":1686},{"nctId":"NCT01613248","phase":"PHASE2","title":"A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-07-01","conditions":"Migraine","enrollment":834},{"nctId":"NCT02828020","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-22","conditions":"Migraine, With or Without Aura","enrollment":1672},{"nctId":"NCT01657370","phase":"PHASE2","title":"A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-08","conditions":"Migraine","enrollment":195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Ubrogepant","genericName":"Placebo for Ubrogepant","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}